99mTc-MIP-1405

Drug Profile

99mTc-MIP-1405

Alternative Names: 99mTc-MIP1405; MIP-1405

Latest Information Update: 16 Jun 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Class Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules; Technetium compounds
  • Mechanism of Action Antigen inhibitors; Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 14 Jun 2012 Discontinued - Phase-I for Prostate cancer in USA (IV)
  • 14 Jun 2012 Efficacy and pharmacokinetics data from a phase I trial in Prostate cancer (diagnosis) released by Molecular Insight Pharmaceuticals
  • 19 Oct 2011 Phase-I clinical trials in Prostate cancer in USA (IV; injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top